MIRA INFORM REPORT

 

 

Report Date :

15.02.2014

 

IDENTIFICATION DETAILS

 

Name :

ERIS LIFESCIENCES PRIVATE LIMITED (w.e.f. 09.02.2007)

 

SOZIN FOLORA TOOK OVER BY ERIS LIFESCIENCES PRIVATE LIMITED

 

 

Formerly Known As :

ERIS LIFESCIENCE PRIVATE LIMITED

 

 

Registered Office :

21, New York Tower - A, Near Muktidham Temple Thaltej Cross Road, Thaltej, Ahmedabad – 380054, Gujarat

 

 

Country :

India

 

 

Financials (as on) :

31.03.2013

 

 

Date of Incorporation :

25.01.2007

 

 

Com. Reg. No.:

04-049867

 

 

Capital Investment / Paid-up Capital :

Rs. 1.375 Millions

 

 

CIN No.:

[Company Identification No.]

U24232GJ2007PTC049867

 

 

TAN No.:

[Tax Deduction & Collection Account No.]

AHME00711E

 

 

PAN No.:

[Permanent Account No.]

AABCE7067M

 

 

Legal Form :

Private Limited Liability Company

 

 

Line of Business :

Manufacturer of Pharmaceuticals and Chemical Products and Medicaments.

 

 

No. of Employees :

Not Available [We tried to confirm the number of employees but no one is ready to part any information from the company management]

 

 

RATING & COMMENTS

 

MIRA’s Rating :

Ba (55)

 

RATING

STATUS

PROPOSED CREDIT LINE

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

Satisfactory

 

Maximum Credit Limit :

USD 5500000

 

 

Status :

Good

 

 

Payment Behaviour :

Regular

 

 

Litigation :

Clear

 

 

Comments :

Subject is a well-established company having fine track record.

 

As claimed by Mr. Rajesh Jain, partner that SOZIN FOLORA has been taken over by ERIS LIFESCIENCES PRIVATE LIMITED during the year 2010.

 

The rating takes into consideration sound financial risk profile marked by decent profitability and adequate liquidity position.

 

Trade relations are reported as fair. Business is active. Payments are reported to be regular and as per commitments.

 

The company can be considered good for normal business dealings at usual trade terms and conditions.

 

NOTES :

Any query related to this report can be made on e-mail : infodept@mirainform.com while quoting report number, name and date.

 

 

ECGC Country Risk Classification List – December 1, 2013

 

Country Name

Previous Rating

(30.09.2013)

Current Rating

(01.12.2013)

India

A1

A1

 

Risk Category

ECGC Classification

Insignificant

 

A1

Low

 

A2

Moderate

 

B1

High

 

B2

Very High

 

C1

Restricted

 

C2

Off-credit

 

D

 

 

INDIAN ECONOMIC OVERVIEW

 

The worst is over for India’s economy with gross domestic product likely to expand 5 %to 5.5 % this year and more than 6 % in 2015, according to Moody’s Analytics. Concerns over the rupee and current account deficit are under control, said the agency. Ratings firm Crisil has forecast 6 % growth for 2014/15 up from the estimated 4.8 % for 2013/14.  Total economic growth, infrastructure bottlenecks and lack of transparency and consistency in foreign direct investment policies seem to have taken a toll on India’s attractiveness as an investment destination, says an Ernst & Young survey.  Projects with FDI component fell 16.4 % across the globe in 2012 from the previous year.  The drop in India was steeper at 21 %. State run carrier Air India is doling out free tickets to its 24000 employees, even as it expects to incur a loss of Rs 39000 mn this financial year and has a debt of Rs 350000 mn. 550000 number of jobs generated across India in 2013, a fall of 0.4 % as compared to with a year earlier. The National  Capital Region has a one-fourth share in total jobs created, according to a study by industry lobby group Assochem, Banks, real estate, automobile and telecommunications sectors are showing a rise of job creation. $ 805 mn investments by venture capital firms in India during 2013, registering a drop of about 18 % over the previous year. The Information Technology and IT-Enabled  Services Industry retained its status as the favourable venture capital investors in 2013. Pakistan has temporarily banned gold imports for the second time in six months, as it tries to stem smuggling into India. India’s import duty on gold is 10 % and curbs on purchases have dried up legal imports into what used to be the world’s biggest bullion buyers. The World Gold Council puts the amount smuggled into India at upto 200 tonnes in 2013. The Reserve Bank of India has proposed that unclaimed bank deposits estimated to be about Rs 35000 mn be used for education and awareness among depositors.  According to the plan, deposits that have not been claimed for at least 10 years will be transferred to the scheme.

 

 

RBI DEFAULTERS’ LIST STATUS

 

Subject’s name is not enlisted as a defaulter in the publicly available RBI Defaulters’ list.

 

 

EPF (Employee Provident Fund) DEFAULTERS’ LIST STATUS

 

Subject’s name is not enlisted as a defaulter in the publicly available EPF (Employee Provident Fund) Defaulters’ list as of 31-03-2012.

 

 

INFORMATION DECLINED

 

MANAGEMENT NON-COOPERATIVE (Tel. No.: 91-79-30451000)

 

 

LOCATIONS

 

Registered Office :

21, New York Tower - A, Near Muktidham Temple Thaltej Cross Road, Thaltej, Ahmedabad – 380054, Gujarat, India

Tel. No. :

91-79-30451000

Fax No. :

Not Available

E-Mail :

ho.admin@erislifesciences.com

efficientbs@gmail.Com   

 

 

DIRECTORS

 

As on 11.09.2013

 

Name :

Mr. Amit Indubhushan Bakshi

Designation :

Managing director

Address :

1, Amrakadam Co-Operative Housing Society, Opposite Shukan Flats, Ramdevnagar, Satellite, Ahmedabad – 380015, Gujarat, India

Date of Birth/Age :

28.11.1974

Date of Appointment :

01.04.2011

PAN No.:

AGIPB4441Q

DIN No. :

01250925

Other Directorship :

S.No.

CIN/LLPIN

Name of the Company/ LLP

Current designation of the Director/ Designated Partner

Date of appointment at current designation

Original date of appointment

Date of cessation

Company/ LLP Status

Defaulting status

1

U24232GJ2007PTC049867

ERIS LIFESCIENCES PRIVATE LIMITED

Managing director

01/04/2011

27/01/2007

-

Active

NO

2

U24230GJ2009PTC057670

ERIS THERAPEUTICS PRIVATE LIMITED

Director

30/07/2009

30/07/2009

-

Active

NO

3

U92412GJ2009PTC056743

SKY WANDERERS PRIVATE LIMITED

Director

20/02/2010

20/02/2010

03/11/2011

Active

NO

4

U55200GJ2010PTC061453

VIRGO RESTAURANTS PRIVATE LIMITED

Director

06/07/2010

06/07/2010

28/02/2012

Active

NO

5

U74900HR2011PTC041889

BIG BUCKS ONLINE SHOPPING PRIVATE LIMITED

Director

10/03/2011

10/03/2011

31/03/2012

Active

NO

6

U24239GJ2012PTC069999

ERIS FORMULATIONS PRIVATE LIMITED

Whole-time director

20/04/2012

20/04/2012

-

Active

NO

 

 

Name :

Mr. Himanshu Jayantbhai Shah

Designation :

Director

Address :

A/74, Yash Tower, Near Shwetanjali Society, Opposite Hasubhai Park, Jodhpur Gam, Ahmedabad - 380018, Gujarat, India

Date of Birth/Age :

09.04.1976

Date of Appointment :

27.01.2007

DIN No. :

01301025

Other Directorship :

S.No.

CIN/LLPIN

Name of the Company/ LLP

Current designation of the Director/ Designated Partner

Date of appointment at current designation

Original date of appointment

Company/ LLP Status

Defaulting status

1

U24232GJ2007PTC049867

ERIS LIFESCIENCES PRIVATE LIMITED

Director

27/01/2007

27/01/2007

Active

NO

2

U24230GJ2009PTC057670

ERIS THERAPEUTICS PRIVATE LIMITED

Director

25/11/2009

25/11/2009

Active

NO

3

U24239GJ2012PTC069999

ERIS FORMULATIONS PRIVATE LIMITED

Whole-time director

20/04/2012

20/04/2012

Active

NO

 

 

Name :

Mr. Rajendra Rambhai Patel

Designation :

Director

Address :

H-103, Akash - 3, 132ft Ring Road, Naranpura, Ahmedabad – 380013, Gujarat, India

Date of Birth/Age :

16.02.1977

Date of Appointment :

16.08.2012

DIN No. :

01229080

Other Directorship :

S.No.

CIN/LLPIN

Name of the Company/ LLP

Current designation of the Director/ Designated Partner

Date of appointment at current designation

Original date of appointment

Date of cessation

Company/ LLP Status

Defaulting status

1

U24232GJ2007PTC049867

ERIS LIFESCIENCES PRIVATE LIMITED

Director

16/08/2012

27/01/2007

-

Active

NO

2

U24230GJ2009PTC057670

ERIS THERAPEUTICS PRIVATE LIMITED

Director

25/11/2009

25/11/2009

-

Active

NO

 

 

Name :

Mr. Inderjeet Singh Negi

Designation :

Director

Address :

B-22C Rajat Vihar, Sector-62, Noida – 201301, India

Date of Birth/Age :

22.06.1971

Date of Appointment :

25.01.2007

DIN No. :

01255388

Other Directorship :

S.No.

CIN/LLPIN

Name of the Company/ LLP

Current designation of the Director/ Designated Partner

Date of appointment at current designation

Original date of appointment

Company/ LLP Status

Defaulting status

1

U24232GJ2007PTC049867

ERIS LIFESCIENCES PRIVATE LIMITED

Director

25/01/2007

25/01/2007

Active

NO

2

U24230GJ2009PTC057670

ERIS THERAPEUTICS PRIVATE LIMITED

Director

25/11/2009

25/11/2009

Active

NO

 

 

Name :

Mr. Kaushal Kamlesh Shah

Designation :

Director

Address :

2-B, Paradise Park, Opposite Shantinagar Bus Stop, Jain Agan Mandir, Ashram Road, Ahmedabad – 380014, Gujarat, India

Date of Birth/Age :

12.07.1979

Date of Appointment :

27.01.2007

DIN No. :

01229038

Other Directorship :

S.No.

CIN/LLPIN

Name of the Company/ LLP

Current designation of the Director/ Designated Partner

Date of appointment at current designation

Original date of appointment

Company/ LLP Status

Defaulting status

1

U24232GJ2007PTC049867

ERIS LIFESCIENCES PRIVATE LIMITED

Director

27/01/2007

27/01/2007

Active

NO

2

U24230GJ2009PTC057670

ERIS THERAPEUTICS PRIVATE LIMITED

Director

25/11/2009

25/11/2009

Active

NO

 

 

Name :

Mr. Bhikhabhai Chimanlal Shah

Designation :

Director

Address :

Paras '7', Vidhyanagar Society, No. III, Usmanpura, Ahmedabad – 380013, Gujarat, India

Date of Birth/Age :

24.05.1939

Date of Appointment :

25.01.2007

DIN No. :

01217618

Other Directorship :

S.No.

CIN/LLPIN

Name of the Company/ LLP

Current designation of the Director/ Designated Partner

Date of appointment at current designation

Original date of appointment

Date of cessation

Company/ LLP Status

Defaulting status

1

U24232GJ1990PTC014539

KANCHAN PHARMA PRIVATE LIMITED

Director

25/10/1990

25/10/1990

16/01/2012

Active

NO

2

U24232GJ2007PTC049867

ERIS LIFESCIENCES PRIVATE LIMITED

Director

25/01/2007

25/01/2007

-

Active

NO

3

U24230GJ2009PTC057670

ERIS THERAPEUTICS PRIVATE LIMITED

Director

25/11/2009

25/11/2009

-

Active

NO

 

 

Name :

Mr. Sanjiv Dwarkanath Kaul

Designation :

Director

Address :

22, Siris Road, DLF Qutab Enclave, Phase - 3, Gurgaon – 122002, Haryana, India

Date of Birth/Age :

25.07.1957

Date of Appointment :

29.08.2011

DIN No. :

01550413

Other Directorship :

S.No.

CIN/LLPIN

Name of the Company/ LLP

Current designation of the Director/ Designated Partner

Date of appointment at current designation

Original date of appointment

Date of cessation

Company/ LLP Status

Defaulting status

1

U24231GJ1985PLC007866

INTAS PHARMACEUTICALS LIMITED

Nominee director

16/06/2012

05/01/2006

-

Active

NO

2

U85110KA2005PTC035687

BIOQUEST SOLUTIONS PRIVATE LIMITED

Director

25/08/2006

25/08/2006

06/11/2012

Active

NO

3

U74899DL1991PLC044843

MANKIND PHARMA LIMITED

Director

21/09/2007

24/04/2007

-

Active

NO

4

U45200DL2008PTC180377

SAAYA STRUCTURES PRIVATE LIMITED

Director

10/07/2008

10/07/2008

05/09/2009

Strike off

NO

5

U24230GJ2005PLC047111

INTAS BIOPHARMACEUTICALS LIMITED

Director

05/09/2011

02/08/2011

-

Amalgamated

NO

6

U24232GJ2007PTC049867

ERIS LIFESCIENCES PRIVATE LIMITED

Director

29/08/2011

29/08/2011

-

Active

NO

7

U24230GJ2009PTC057670

ERIS THERAPEUTICS PRIVATE LIMITED

Director

29/08/2011

29/08/2011

-

Active

NO

8

U74900DL2012PTC235889

NUVO CHRYSCAPITAL ADVISORS PRIVATE LIMITED

Additional director

21/05/2012

21/05/2012

-

Active

NO

 

 

MAJOR SHAREHOLDERS / SHAREHOLDING PATTERN

 

As on 11.09.2013

 

Names of Shareholders

No. of Shares

Percentage of Holding

Amit Indubhushan Bakshi

51521

37.47

Himanshu Jayantbhai Shah

6972

5.07

Rajendra Rambhai Patel

6971

5.07

Inderjeet Singh Negi

6971

5.07

Kaushal Kamlesh Shah

5500

4.00

Hetal Rasiklal Shah

5500

4.00

Rakesh Bhikhalal Shah

15867

11.54

Bhikhalal Chimanlal Shah

15854

11.53

Botticelli

22344

16.25

Total

137500

100.00

 

 

As on 11.09.2013

 

Equity Share Break up (Percentage of Total Equity)

 

Category

Percentage of Holding

Bodies corporate

16.25

Directors or relatives of Directors

83.75

Total

100.00

 

 

 

 

BUSINESS DETAILS

 

Line of Business :

Manufacturer of Pharmaceuticals and Chemical Products and Medicaments.

 

 

GENERAL INFORMATION

 

No. of Employees :

Not Available [We tried to confirm the number of employees but no one is ready to part any information from the company management]

 

 

Bankers :

·         Bank of Baroda, Navrangpura Branch, Navrangpura, Ahmedabad - 380009, Gujarat, India

HDFC Bank Limited

Axis Bank Limited

 

 

Facilities :

SECURED LOANS

31.03.2013

(Rs. In Millions)

31.03.2012

(Rs. In Millions)

LONG TERM BORROWINGS

 

 

Loans taken for vehicles

0.374

3.810

Total

0.374

3.810

 

Banking Relations :

--

 

 

Auditors :

 

Name :

R R S and Associates

Chartered Accountants

Address :

211, Kamal Complex, Near Stadium Circle Road, C G Road, Ahmedabad, Gujarat, India

Income-tax PAN of auditor or auditor's firm :

AAFFR0472A

 

 

Subsidiary:

Eris Therapeutics Private Limited

CIN No.: U24230GJ2009PTC057670

 

 

Other Related Party:

Sozin Flora Pharma

 

 

CAPITAL STRUCTURE

 

As on 31.03.2013

 

Authorised Capital :

No. of Shares

Type

Value

Amount

 

 

 

 

10,000,000

Equity Shares

Rs.10/- each

Rs.100.000 Millions

 

 

 

 

 

Issued, Subscribed & Paid-up Capital :

No. of Shares

Type

Value

Amount

 

 

 

 

137,500

Equity Shares

Rs.10/- each

Rs.1.375 Millions

 

 

 

 

 


 

FINANCIAL DATA

[all figures are in Rupees Millions]

 

ABRIDGED BALANCE SHEET

 

SOURCES OF FUNDS

 

31.03.2013

31.03.2012

31.03.2011

I.        EQUITY AND LIABILITIES

 

 

 

(1)Shareholders' Funds

 

 

 

(a) Share Capital

1.375

1.375

1.375

(b) Reserves & Surplus

1,373.468

685.558

194.251

(c) Money received against share warrants

0.000

0.000

0.000

 

 

 

 

(2) Share Application money pending allotment

0.000

0.000

0.000

Total Shareholders’ Funds (1) + (2)

1,374.843

686.933

195.626

 

 

 

 

(3) Non-Current Liabilities

 

 

 

(a) long-term borrowings

0.374

25.809

37.078

(b) Deferred tax liabilities (Net)

0.000

1.804

2.624

(c) Other long term liabilities

0.000

0.000

0.000

(d) long-term provisions

0.000

0.000

0.000

Total Non-current Liabilities (3)

0.374

27.613

39.702

 

 

 

 

(4) Current Liabilities

 

 

 

(a) Short term borrowings

35.345

7.477

0.000

(b) Trade payables

159.488

115.591

138.295

(c) Other current liabilities

46.164

41.125

34.980

(d) Short-term provisions

34.309

22.880

196.827

Total Current Liabilities (4)

275.306

187.073

370.102

 

 

 

 

TOTAL

1,650.523

901.619

605.430

 

 

 

 

II.      ASSETS

 

 

 

(1) Non-current assets

 

 

 

(a) Fixed Assets

 

 

 

(i) Tangible assets

148.280

105.865

65.049

(ii) Intangible Assets

0.745

0.487

0.209

(iii) Capital work-in-progress

0.000

0.000

0.000

(iv) Intangible assets under development

0.000

0.000

0.000

(b) Non-current Investments

115.515

56.679

27.149

(c) Deferred tax assets (net)

0.557

0.000

0.000

(d)  Long-term Loan and Advances

0.000

0.000

11.094

(e) Other Non-current assets

0.000

0.000

0.000

Total Non-Current Assets

265.097

163.031

103.501

 

 

 

 

(2) Current assets

 

 

 

(a) Current investments

465.000

134.516

51.781

(b) Inventories

519.682

230.628

162.229

(c) Trade receivables

163.102

141.839

73.299

(d) Cash and cash equivalents

35.164

88.634

3.855

(e) Short-term loans and advances

202.478

142.971

210.765

(f) Other current assets

0.000

0.000

0.000

Total Current Assets

1,385.426

738.588

501.929

 

 

 

 

TOTAL

1,650.523

901.619

605.430

 

 

 

PROFIT & LOSS ACCOUNT

 

 

PARTICULARS

31.03.2013

 

31.03.2012

31.03.2011

 

SALES

 

 

 

 

 

Income

4488.124

3055.896

1652.394

 

 

Other Income

NA

NA

NA

 

 

TOTAL                                    

NA

NA

NA

 

 

 

 

 

Less

EXPENSES

 

 

 

 

 

TOTAL                                    

NA

NA

NA

 

 

 

 

 

 

PROFIT/ (LOSS)  BEFORE TAX 

NA

662.587

305.067

 

 

 

 

 

Less

TAX                                                                 

NA

171.280

101.950

 

 

 

 

 

 

PROFIT/ (LOSS)  AFTER TAX

687.910

491.307

203.117

 

 

 

 

 

 

EARNINGS IN FOREIGN CURRENCY

0.000

0.000

71.891

 

 

 

 

 

 

Earnings / (Loss) Per Share (Rs.)

5002.98

3573.14

1477.21

 

 

KEY RATIOS

 

PARTICULARS

 

 

31.03.2013

31.03.2012

31.03.2011

 

 

 

 

 

Net Profit Margin

(PBT/Sales)

(%)

NA

21.68

18.46

 

 

 

 

 

Return on Total Assets

(PBT/Total Assets}

(%)

NA

78.42

52.75

 

 

 

 

 

Return on Investment (ROI)

(PBT/Networth)

 

NA

0.96

1.56

 

 

 

 

 

Debt Equity Ratio

(Total Debt/Networth)

 

0.03

0.05

0.19

 

 

 

 

 

Current Ratio

(Current Asset/Current Liability)

 

5.03

3.95

1.36

 

 

FINANCIAL ANALYSIS

[all figures are in Rupees Millions]

 

DEBT EQUITY RATIO

 

Particular

31.03.2011

31.03.2012

31.03.2013

 

(Rs. In Millions)

(Rs. In Millions)

(Rs. In Millions)

Share Capital

1.375

1.375

1.375

Reserves & Surplus

194.251

685.558

1373.468

Net worth

195.626

686.933

1374.843

 

 

 

 

long-term borrowings

37.078

25.809

0.374

Short term borrowings

0.000

7.477

35.345

Total borrowings

37.078

33.286

35.719

Debt/Equity ratio

0.190

0.048

0.026

 

 

 

YEAR-ON-YEAR GROWTH

 

Year on Year Growth

31.03.2011

31.03.2012

31.03.2013

 

(Rs. In Millions)

(Rs. In Millions)

(Rs. In Millions)

 

1652.394

3055.896

4488.124

 

 

84.937

46.868

 

 

 

NET PROFIT MARGIN

 

Net Profit Margin

31.03.2011

31.03.2012

31.03.2013

 

(Rs. In Millions)

(Rs. In Millions)

(Rs. In Millions)

Sales

1652.394

3055.896

4488.124

Profit

203.117

491.307

687.910

 

0.123

0.161

0.153

 

 

 

LOCAL AGENCY FURTHER INFORMATION

 

Sr. No.

Check List by Info Agents

Available in Report (Yes / No)

1]

Year of Establishment

Yes

2]

Locality of the firm

Yes

3]

Constitutions of the firm

Yes

4]

Premises details

No

5]

Type of Business

Yes

6]

Line of Business

Yes

7]

Promoter's background

Yes

8]

No. of employees

No

9]

Name of person contacted

No

10]

Designation of contact person

No

11]

Turnover of firm for last three years

Yes

12]

Profitability for last three years

Yes

13]

Reasons for variation <> 20%

-----

14]

Estimation for coming financial year

No

15]

Capital in the business

Yes

16]

Details of sister concerns

Yes

17]

Major suppliers

No

18]

Major customers

No

19]

Payments terms

No

20]

Export / Import details (if applicable)

No

21]

Market information

-----

22]

Litigations that the firm / promoter involved in

-----

23]

Banking Details

Yes

24]

Banking facility details

Yes

25]

Conduct of the banking account

-----

26]

Buyer visit details

-----

27]

Financials, if provided

Yes

28]

Incorporation details, if applicable

Yes

29]

Last accounts filed at ROC

Yes

30]

Major Shareholders, if available

Yes

31]

Date of Birth of Proprietor/Partner/Director, if available

Yes

32]

PAN of Proprietor/Partner/Director, if available

Yes

33]

Voter ID No of Proprietor/Partner/Director, if available

No

34]

External Agency Rating, if available

No

 

 

INDEX OF CHARGES: NO CHARGES EXIST FOR COMPANY

 

 

UNSECURED LOANS

 

PARTICULAR

31.03.2013

(Rs. In Millions)

31.03.2012

(Rs. In Millions)

LONG TERM BORROWINGS

 

 

Other loans and advances, others

0.000

21.999

 

 

 

SHORT TERM BORROWINGS

 

 

Working capital loans from banks

35.345

7.477

Total

35.345

29.476

 

 

CHANGE OF ADDRESS

 

The registered office of the company has been shifted from A/F-10, Kanchan Pharma House, Aslali, Ahmedabad – 382427, Gujarat, India to the present address w.e.f. 08.05.2012.

 

 

COMPANIES AFFAIR

 

During the year, the company has continued its growth momentum, and has achieved total operational revenue of Rs.4488.124 Millions compared to Rs.3055.896 Millions Lacs in the previous year, recording a growth of 46.87%.

 

 

FIXED ASSETS

 

v                  Tangible Assets

Land

Buildings

Furniture and Fixtures

Vehicles

Motor Vehicles

Office Equipment

Computer Equipments

Books Periodicals

Other equipments

 

v                 Intangible Assets

Brands and Trade Marks

 


 

CMT REPORT (Corruption, Money Laundering & Terrorism]

 

The Public Notice information has been collected from various sources including but not limited to: The Courts, India Prisons Service, Interpol, etc.

 

1]         INFORMATION ON DESIGNATED PARTY

No exist designating subject or any of its beneficial owners, controlling shareholders or senior officers as terrorist or terrorist organization or whom notice had been received that all financial transactions involving their assets have been blocked or convicted, found guilty or against whom a judgement or order had been entered in a proceedings for violating money-laundering, anti-corruption or bribery or international economic or anti-terrorism sanction laws or whose assets were seized, blocked, frozen or ordered forfeited for violation of money laundering or international anti-terrorism laws.

 

2]         Court Declaration :

No exist to suggest that subject is or was the subject of any formal or informal allegations, prosecutions or other official proceeding for making any prohibited payments or other improper payments to government officials for engaging in prohibited transactions or with designated parties.

 

3]         Asset Declaration :

No records exist to suggest that the property or assets of the subject are derived from criminal conduct or a prohibited transaction.

 

4]         Record on Financial Crime :

            Charges or conviction registered against subject:                                                  None

 

5]         Records on Violation of Anti-Corruption Laws :

            Charges or investigation registered against subject:                                                          None

 

6]         Records on Int’l Anti-Money Laundering Laws/Standards :

            Charges or investigation registered against subject:                                                          None

 

7]         Criminal Records

No available information exist that suggest that subject or any of its principals have been formally charged or convicted by a competent governmental authority for any financial crime or under any formal investigation by a competent government authority for any violation of anti-corruption laws or international anti-money laundering laws or standard.

 

8]         Affiliation with Government :

No record exists to suggest that any director or indirect owners, controlling shareholders, director, officer or employee of the company is a government official or a family member or close business associate of a Government official.

 

9]         Compensation Package :

Our market survey revealed that the amount of compensation sought by the subject is fair and reasonable and comparable to compensation paid to others for similar services.

 

10]        Press Report :

            No press reports / filings exists on the subject.

 

CORPORATE GOVERNANCE

 

MIRA INFORM as part of its Due Diligence do provide comments on Corporate Governance to identify management and governance. These factors often have been predictive and in some cases have created vulnerabilities to credit deterioration.

 

Our Governance Assessment focuses principally on the interactions between a company’s management, its Board of Directors, Shareholders and other financial stakeholders.

 

 

CONTRAVENTION

 

Subject is not known to have contravened any existing local laws, regulations or policies that prohibit, restrict or otherwise affect the terms and conditions that could be included in the agreement with the subject.

 

 

FOREIGN EXCHANGE RATES

 

Currency

Unit

Indian Rupees

US Dollar

1

Rs.62.27

UK Pound

1

Rs.103.47

Euro

1

Rs.84.87

 

 

INFORMATION DETAILS

 

Information Gathered by :

NYA

 

 

Report Prepared by :

MRI

 


 

SCORE & RATING EXPLANATIONS

 

SCORE FACTORS

 

RANGE

POINTS

HISTORY

1~10

6

PAID-UP CAPITAL

1~10

6

OPERATING SCALE

1~10

6

FINANCIAL CONDITION

 

 

--BUSINESS SCALE

1~10

6

--PROFITABILIRY

1~10

7

--LIQUIDITY

1~10

6

--LEVERAGE

1~10

6

--RESERVES

1~10

6

--CREDIT LINES

1~10

6

--MARGINS

-5~5

--

DEMERIT POINTS

 

 

--BANK CHARGES

YES/NO

YES

--LITIGATION

YES/NO

NO

--OTHER ADVERSE INFORMATION

YES/NO

NO

MERIT POINTS

 

 

--SOLE DISTRIBUTORSHIP

YES/NO

NO

--EXPORT ACTIVITIES

YES/NO

NO

--AFFILIATION

YES/NO

YES

--LISTED

YES/NO

NO

--OTHER MERIT FACTORS

YES/NO

YES

DEFAULTER

 

 

--RBI

YES/NO

NO

--EPF

YES/NO

NO

TOTAL

 

55

 

This score serves as a reference to assess SC’s credit risk and to set the amount of credit to be extended. It is calculated from a composite of weighted scores obtained from each of the major sections of this report. The assessed factors and their relative weights (as indicated through %) are as follows:

 

Financial condition (40%)            Ownership background (20%)                 Payment record (10%)

Credit history (10%)                    Market trend (10%)                                Operational size (10%)

 


 

RATING EXPLANATIONS

 

RATING

STATUS

 

 

PROPOSED CREDIT LINE

>86

Aaa

Possesses an extremely sound financial base with the strongest capability for timely payment of interest and principal sums

 

Unlimited

71-85

Aa

Possesses adequate working capital. No caution needed for credit transaction. It has above average (strong) capability for payment of interest and principal sums

 

Large

56-70

A

Financial & operational base are regarded healthy. General unfavourable factors will not cause fatal effect. Satisfactory capability for payment of interest and principal sums

 

Fairly Large

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

 

Satisfactory

26-40

B

Capability to overcome financial difficulties seems comparatively below average.

 

Small

11-25

Ca

Adverse factors are apparent. Repayment of interest and principal sums in default or expected to be in default upon maturity

 

Limited with full security

<10

C

Absolute credit risk exists. Caution needed to be exercised

 

 

Credit not recommended

--

NB

                                       New Business

 

--

 

 

 

 

PRIVATE & CONFIDENTIAL : This information is provided to you at your request, you having employed MIPL for such purpose. You will use the information as aid only in determining the propriety of giving credit and generally as an aid to your business and for no other purpose. You will hold the information in strict confidence, and shall not reveal it or make it known to the subject persons, firms or corporations or to any other. MIPL does not warrant the correctness of the information as you hold it free of any liability whatsoever. You will be liable to and indemnify MIPL for any loss, damage or expense, occasioned by your breach or non observance of any one, or more of these conditions

This report is issued at your request without any risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL) or its officials.